RadNet, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Howard G. Berger
- Full Time Employees
- 9,060
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 1508, 1510 and 1516 Cotner Avenue Los Angeles CA United States of America 90025
- IPO Date
- Jan 3, 1997
- CIK
- 0000790526
- Website
- radnet.com
- Similar Companies
- Business
- RadNet, Inc. (NYSE: RDNT) operates as a leading national provider of freestanding outpatient diagnostic imaging services in the United States. The company offers a comprehensive range of medical imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy, and other related services; it also provides image exchange networks, teleradiology services, and artificial intelligence (AI)-assisted diagnostic tools under brands such as DeepHealth for AI applications. RadNet serves patients, referring physicians, health systems, and health plans through a network of over 380 imaging centers across major markets including California, New York, New Jersey, Maryland, Delaware, Florida, and Connecticut. Founded in 1980 and headquartered in Los Angeles, California, the company focuses on high-quality, cost-effective outpatient imaging in the healthcare services industry, targeting urban and suburban demographics with a mix of fixed-site centers and joint ventures with hospitals. In recent developments, RadNet expanded its footprint through the acquisition of several imaging centers and strategic joint ventures, including a significant partnership with Hackensack Meridian Health in New Jersey during 2024; it also launched new AI-enhanced breast imaging solutions and completed a major funding round via convertible notes to support growth initiatives. The company reported robust revenue growth in 2025, driven by volume increases and reimbursement improvements, alongside the opening of new facilities in high-density markets. RadNet maintains no major subsidiaries but operates through various joint ventures and has pursued aggressive de novo expansion in the Southeast and Midwest regions.
RadNet: Imaging And AI Keep The Bull Case Intact
RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised
RadNet (NASDAQ:RDNT) Trading Up 6.9% on Earnings Beat
RadNet, Inc. (RDNT) Q2 2026 Earnings Call Transcript
RadNet Q2 Earnings Call Highlights
RadNet Reports Strong Q2 Results, Boosting Investor Confidence
RadNet (RDNT) Reports Q2 Earnings: What Key Metrics Have to Say
RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges
Countdown to RadNet (RDNT) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound
5 Takeover Targets for the AI Revolution
RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call
Bessemer Group Inc. Has $30.75 Million Stock Position in RadNet, Inc. $RDNT
RDNT's Unit DeepHealth Expands AI Breast Suite With FDA-Cleared Tools
DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite
RadNet Inc (RDNT) Stock Up 3.8% and Still Undervalued -- GF Score: 79/100
Is It Too Late to Buy RadNet Inc (RDNT) After 3.5% Rally? GF Value Says Undervalued
RadNet Secures $250 Million Incremental Term Loan to Fund Strategic Growth Opportunities and Reduces the Interest Rates on its Credit Facility by 0.25%
DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting
RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities